Retinopathy
≈ 4 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Retinopathy is any damage to the retina of the eyes, which may cause vision impairment. Retinopathy often refers to retinal vascular disease, or damage to the retina caused by abnormal blood flow. Age-related macular degeneration is technically included under the umbrella term retinopathy but is often discussed as a separate entity.
Retinopathy, or retinal vascular disease, can be broadly categorized into proliferative and non-proliferative types. Frequently, retinopathy is an ocular manifestation of systemic disease as seen in diabetes or hypertension. Diabetes is the most common cause of retinopathy in the U.S. as of 2008.
Diabetic retinopathy is the leading cause of blindness in working-aged people. It accounts for about 5% of blindness worldwide and is designated a priority eye disease by the World Health Organization.
Retinopathy is any damage to the retina of the eyes, which may cause vision impairment. Retinopathy often refers to retinal vascular disease, or damage to the retina caused by abnormal blood flow. Age-related macular degeneration is technically included under the umbrella term retinopathy but is often discussed as a separate entity.
Retinopathy, or retinal vascular disease, can be broadly categorized into proliferative and non-proliferative types. Frequently, retinopathy is an ocular manifestation of systemic disease as seen in diabetes or hypertension. Diabetes is the most common cause of retinopathy in the U.S. as of 2008.
Diabetic retinopathy is the leading cause of blindness in working-aged people. It accounts for about 5% of blindness worldwide and is designated a priority eye disease by the World Health Organization.
Pathophysiology
The development of retinopathy can be broken down into proliferative and non-proliferative types. Both types cause disease by altering the normal blood flow to the retina through different mechanisms. The retina is supplied by small vessel branches from the central retinal artery.
Proliferative retinopathy refers to damage caused by abnormal blood vessel growth. Normally, angiogenesis is a natural part of tissue growth and formation. When there is an unusually high or fast rate of angiogenesis, there is an overgrowth of blood vessels called neovascularization.
In the non-proliferative type, abnormal blood flow to the retina occurs due to direct damage or compromise of the blood vessels themselves. Many causes of retinopathy may cause both proliferative and non-proliferative types, though some causes are more associated one type.
Prevention
Retinopathy is often secondary to diseases such as diabetes or hypertension. Controlling blood sugar levels and blood pressure have been shown to help decrease incidence of retinopathy. Blood sugar control: If someone has diabetes, or is at high risk for diabetes, it is important for them to have their blood sugar levels checked.
The gold standard blood sugar test is the HbA1C test. Many studies have suggested that lowering HbA1C levels in someone with elevated HbA1C levels can lower the incidence and progression of retinopathy. Fortunately, blood sugar control can have benefits beyond just the eye.
A primary care physician can help with blood sugar control strategies. Blood pressure control: Controlling blood pressure can also lower the incidence and progression of retinopathy. A primary care physician can help with blood pressure control strategies.
Other: Besides blood sugar and blood pressure control, there are other modifications that can help. Regular exercise may help lower the incidence and progression of retinopathy. If someone has sleep apnea, treatment of sleep apnea may help as well.
Treatment
Treatment is based on the cause of the retinopathy and may include laser therapy to the retina. Laser photocoagulation therapy has been the standard treatment for many types of retinopathy. Evidence shows that laser therapy is generally safe and improves visual symptoms in sickle cell and diabetic retinopathy.
In recent years targeting the pathway controlling vessel growth or angiogenesis has been promising. Vascular endothelial growth factor (VEGF) seems to play a vital role in promoting neovascularization. Using anti-VEGF drugs (antibodies to sequester the growth factor), research have shown significant reduction in the extent of vessel outgrowth.
Low quality evidence supports the use of anti-VEGF antibodies, such as bevacizumab or pegaptanib which seems to improve outcomes when used in conjunction with laser therapy to treat retinopathy of prematurity, longer term systemic effects are not known however. The evidence is poorer for treatment of diabetic retinopathy.
Use of anti-VEGF drugs did not appear to improve outcomes in a clinically significant way when compared to standard laser therapy for diabetic retinopathy.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374002791 under CC BY-SA 4.0; modifications have been made.